Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 0.66 |
| ▸ | HTT | P42858 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | CTSD | P07339 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9647861 | 0.85 | HPGD (0.65) | HPGDHTTALDH1A1CTSDSMN1; SMN2 | |
| SCHEMBL3213334 | 0.84 | HPGD (0.50) | HPGDHTTALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL3198208 | 0.84 | POLB (0.57) | HPGDHTTALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL6715984 | 0.82 | HPGD (0.57) | HPGDHTTALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL9646732 | 0.81 | HPGD (0.72) | HPGDHTTALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL4717003 | 0.81 | HPGD (0.47) | HPGDHTTALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL16840300 | 0.80 | HPGD (0.69) | HPGDHTTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL6454393 | 0.80 | ALDH1A1 (0.73) | HTTALDH1A1SMN1; SMN2TDP1MEN1 | |
| SCHEMBL9645054 | 0.80 | HPGD (1.00) | HPGDHTTALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL23083259 | 0.79 | SMN1; SMN2 (0.62) | HPGDHTTALDH1A1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221371-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-08-07 | — | — | US | disclosed |
| US-20100041698-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221371-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, HTR1A, HTR2C | HPGD 1244/4885HTT 75/4885ALDH1A1 1897/4885 |
| US-20100041698-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, HTR1A, HTR2C | HPGD 1244/4885HTT 75/4885ALDH1A1 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.